Patents by Inventor Monica Schenone

Monica Schenone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12
    Publication number: 20220071995
    Abstract: The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
    Type: Application
    Filed: November 18, 2021
    Publication date: March 10, 2022
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Pharma Aktiengesellschaft
    Inventors: Luc De Waal, Matthew Meyerson, Heidi Greulich, Monica Schenone, Alex Burgin, Xiaoyun Wu, Ulrike Sack
  • Compositions and methods for cancer expressing PDE3A or SLFN12
    Patent number: 11207320
    Abstract: The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: December 28, 2021
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Pharma Aktiengesellschaft
    Inventors: Luc De Waal, Matthew Meyerson, Heidi Greulich, Monica Schenone, Alex Burgin, Xiaoyun Wu, Ulrike Sack
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT
    Publication number: 20210236504
    Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Application
    Filed: January 28, 2021
    Publication date: August 5, 2021
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILIP LIENAU, ULRIKE SACK, MARTIN LANGE
  • Compounds, compositions and methods for cancer patient stratification and cancer treatment
    Patent number: 10966986
    Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: April 6, 2021
    Assignees: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE INC.
    Inventors: Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT
    Publication number: 20190365770
    Abstract: The present invention features improved Compounds, especially (I) methods of identifying patients having Cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
    Type: Application
    Filed: February 3, 2017
    Publication date: December 5, 2019
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: TIMOTHY A. LEWIS, ALEX BURGIN, MONICA SCHENONE, XIAOYUN WU, HEIDI GREULICH, MATTHEW MEYERSON, LUC DE WAAL, ANTJE MARGRET WENGNER, KNUT EIS, PHILLIP LIENAU, ULRIKE SACK, MARTIN LANGE
  • COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12
    Publication number: 20180235961
    Abstract: The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Pharma AG
    Inventors: Luc De Waal, Matthew Meyerson, Heidi Greulich, Monica Schenone, Alex Burgin, Xiaoyun Wu, Ulrike Sack